myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Barry Skikne, MD

Skikne, Barry
Hematologist
Westwood Medical Pavilion and the Richard and Annette Bloch Cancer Care Pavilion

Dr. Barry Skikne is certified by the American Board of Internal Medicine with a subcertification in hematology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Witwatersrand and completed his residency at Johannesburg Hospital.

Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

Author(s): 
Gorshein E, Weber UM, Gore S
Primary Author: 
Gorshein E
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Mar 2020

Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to

Bone Marrow Diseases: